IMUC
EOM PHARMACEUTICAL HLDNGSstockOTC
immunocellular therapeutics, ltd. is a los angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. immunocellular has concluded a phase 2 trial of its lead product candidate, ict-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. immunocellular's pipeline also includes: ict-121, a dendritic cell immunotherapy targeting the cd133 antigen on stem cells in recurrent glioblastoma; ict-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the stem-to-t-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing t-cells.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1M | 0.12 | 2026-10-21 | +30.38% | -22.748 |
| 3M | 0.14 | 2026-08-18 | +12.50% | -7.969 |
| 6M | 0.12 | 2026-05-15 | +36.96% | -3.634 |
| 1Y | 0.18 | 2025-11-18 | -12.01% | -1.760 |
| 2Y | 0.20 | 2024-11-18 | -21.25% | — |
| 5Y | 0.56 | 2021-11-18 | -71.88% | 0.253 |
EOM PHARMACEUTICAL HLDNGS (OTC:IMUC) stock price today is $0.16, and today's volume is 5,601. IMUC is down 0.190% today. The 30 day average volume is 3,465. IMUC market cap is $17.84M with 113.27M shares outstanding.
